Health Catalyst, Inc. (NASDAQ:HCAT) Receives Consensus Rating of "Hold" from Analysts

Key Points

• Health Catalyst has a consensus “Hold” rating from 13 analysts: eight holds, four buys and one sell. The average 12-month price target is $2.95.
• Recent analyst actions were mixed, with Canaccord Genuity raising its target to $3.00 and maintaining a buy rating, while Stephens and Citigroup lowered their targets and retained neutral-equivalent ratings.
• Health Catalyst reported quarterly EPS of $0.04, beating estimates by $0.01, and revenue of $70.49 million versus the $69.09 million consensus. However, the company remains unprofitable, with a negative net margin of 90.61%, and institutional investors own approximately 85% of the stock.

Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) has earned an average rating of "Hold" from the thirteen analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $2.9545.

A number of research analysts have issued reports on HCAT shares. Stephens decreased their price target on shares of Health Catalyst from $2.00 to $1.75 and set an "equal weight" rating for the company in a report on Tuesday, May 12th. Canaccord Genuity Group boosted their price objective on shares of Health Catalyst from $2.00 to $3.00 and gave the company a "buy" rating in a report on Tuesday, July 21st. Citigroup cut their target price on Health Catalyst from $2.50 to $2.00 and set a "neutral" rating on the stock in a research report on Tuesday. Wells Fargo & Company raised their target price on Health Catalyst from $1.00 to $1.75 and gave the stock an "equal weight" rating in a research note on Friday, June 26th. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating on shares of Health Catalyst in a research report on Monday, May 11th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of HCAT. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Health Catalyst by 7.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,047 shares of the company's stock valued at $163,000 after acquiring an additional 2,624 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Health Catalyst by 19.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,491 shares of the company's stock worth $100,000 after acquiring an additional 4,341 shares in the last quarter. BNP Paribas Financial Markets raised its position in Health Catalyst by 71.7% during the third quarter. BNP Paribas Financial Markets now owns 16,355 shares of the company's stock worth $47,000 after acquiring an additional 6,832 shares during the period. Invesco Ltd. lifted its holdings in Health Catalyst by 6.5% during the fourth quarter. Invesco Ltd. now owns 118,591 shares of the company's stock valued at $283,000 after purchasing an additional 7,186 shares in the last quarter. Finally, Williams & Novak LLC lifted its holdings in Health Catalyst by 47.2% during the fourth quarter. Williams & Novak LLC now owns 30,235 shares of the company's stock valued at $72,000 after purchasing an additional 9,700 shares in the last quarter. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Health Catalyst Price Performance

Shares of HCAT stock opened at $1.76 on Wednesday. Health Catalyst has a fifty-two week low of $0.96 and a fifty-two week high of $3.80. The company has a debt-to-equity ratio of 1.10, a quick ratio of 1.69 and a current ratio of 1.69. The firm has a market capitalization of $132.46 million, a price-to-earnings ratio of -0.48 and a beta of 1.55. The stock's 50-day simple moving average is $2.00 and its 200-day simple moving average is $1.70.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.03 by $0.01. The firm had revenue of $70.49 million during the quarter, compared to analyst estimates of $69.09 million. Health Catalyst had a negative net margin of 90.61% and a negative return on equity of 1.57%. As a group, equities analysts forecast that Health Catalyst will post -0.25 earnings per share for the current fiscal year.

About Health Catalyst

Health Catalyst NASDAQ: HCAT is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst's offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source